An Overview of GLP-1 RAs for CV Risk Reduction in T2DM Patients
GLP-1 RAs have carved an important role in the management of patients with type 2 diabetes (T2D), not only in glycemic control, but also in reducing cardiovascular and renal risk. The evolving evidence with GLP-1 RA in this setting has led to important studies and guideline changes, all with significant implications for patient management. This interactive infographic activity will walk you through these updates by using high-impact visuals to summarize the evidence, as well as added expert perspectives.
This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), registered nurses, nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, dieticians, and other allied health professionals.
After completing this activity, the participant should be better able to:
- Summarize the mechanisms of action, different properties, as well as efficacy and safety of GLP-1 RAs, alone or in combination, for the management of T2DM.
- Interpret the current evidence from CVOTs and real-world studies with GLP-1 RAs and their practice implications in managing T2DM patients with CVD or at CVD risk.
- Review the recent guideline updates about the individualization of T2DM therapy in patients with existing CVD or CVD risk.
- Develop individualized treatment strategies for patients with T2DM that optimize glycemic control and reduce overall CVD risk.
|Available GLP-1 RAs and Indications
|Completed Cardiovascular Outcomes Trials in T2DM
|Current Guidelines About the Use of GLP-1 RAs in T2DM
|Potential Benefits of GLP-1 on CVD Risk
Vanita R. Aroda, MD (Chair)
Director, Diabetes Clinical Research
Brigham and Women’s Hospital
Harvard Medical School
Dr. Aroda discloses the following:
Consulting Fees: Applied Therapeutics, Duke, Novo Nordisk, Pfizer, Sanofi
Contracted Research: Applied Therapeutics/Medpace; Eli Lilly; Premier/Fractyl; Novo Nordisk; Sanofi/Medpace
Other: Spouse was/is an employee of Merck, Janssen, respectively
Darren G. McGuire, MD, MHSc
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Parkland Health and Hospital System
Dr. McGuire discloses the following:
Consulting Fees: Lilly USA, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Applied Therapeutics, Metavant, Sanofi, Afimmune, Lexicon, CSL Behring, Bayer
Other: Honoraria for Trial Leadership: Boehringer Ingelheim, Sanofi, AstraZeneca, Merck & Co., Pfizer, Novo Nordisk, Esperion, Lilly USA, Lexicon, CSL Behring
Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute; Adjunct
Professor of Medicine, Johns Hopkins University School of Medicine
Dr. Pratley discloses the following:
Grants from Hanmi Pharmaceutical Co., Janssen
Consulting, speaker fees from Merck
Grants, speaker fees and consulting fees from Novo Nordisk
Consulting fees from Pfizer
Grants from Poxel SA
Grants and consulting fees from Sanofi
Consulting fees from Scohia Pharma Inc.
Consulting fees from Sun Pharmaceutical Industries
All honoraria directed toward a non-profit which supports education and research
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
This activity is supported by an educational grant from Novo Nordisk.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.
CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-22-099-H01-P
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
CONTINUING DIETICIAN EDUCATION
This program offers 1.0 CPEUs for dieticians.
ABIM MOC CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The PIM planners and others have nothing to disclose. The CMHC planners and others have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period April 6, 2022 through April 6, 2023, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For questions about the accreditation of this activity, please visit www.pimed.com.
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
- 1.00 ABIM MOC and AMA PRA Category 1 Credit™
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 CDE
- 1.00 Participation
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.